TROVAX Phase III TRIST Study

RNS Number : 1335Z

Oxford Biomedica PLC

15 July 2008

 



FOR IMMEDIATE RELEASE

15 JULY 2008

OXFORD BIOMEDICA REPORTS FURTHER DATA FROM INTERIM REVIEW OF TROVAX® PHASE III TRIST STUDY

Oxford, UK - 15 July 2008: Oxford BioMedica (LSE: OXB), announced that it has written to all investigators participating in the TRIST study summarising the background to the independent Data Safety Monitoring Board's recent recommendations. The letter also summarises the study procedures to continue the follow up of all patients enrolled into the study. 

This letter has been made publically available on the Company's web site at http://www.oxfordbiomedica.co.uk/pdfs/investigators.pdf

Oxford BioMedica is grateful to all investigators participating in TRIST for their continued support of this important ongoing study.

-Ends-

For further information, please contact:
Oxford BioMedica plc:  Mike McDonald, Chief Executive Officer Nick Woolf, Chief Business Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Communications	Tel: [phone]
Scientific/Trade Press Enquiries: Holly Griffiths/ Katja Stout/ Claire Mosley College Hill Life Sciences	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in cancer immunotherapy and gene-based therapies. The Company was established in 1995, as a spin-out from Oxford University, and is listed on the London Stock Exchange. 

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. TroVax® is the Company's therapeutic vaccine, which is in clinical development for multiple solid cancers. The product is licensed to sanofi-aventis for global development and commercialisation. Oxford BioMedica has three other products in clinical development, including ProSavin®, a novel gene-based treatment for Parkinson's disease, in a Phase I/II trial. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 85. Oxford BioMedica has collaborations with sanofi-aventis, Wyeth, Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

2. TroVax® 

TroVax is Oxford BioMedica's novel therapeutic cancer vaccine, which is being developed in collaboration with sanofi-aventis. It is designed specifically to stimulate an anti-cancer immune response and has potential application in most solid tumour types. TroVax targets the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours. The presence of 5T4 is correlated with poor prognosis. The product consists of a Modified Vaccinia Ankara vector, which delivers the gene for 5T4 and stimulates a patient's body to produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the 5T4 antigen.

 

END

 

 

MSCGUUBUMUPRGAA